STAT May 2, 2024
Adam Feuerstein, Allison DeAngelis

The removal of small amounts of brain tissue from desperately ill patients, done as part of a Mount Sinai research project, triggered alarm bells at the Food and Drug Administration and has raised broader questions about the scientific and ethical justification for live-brain research. Journalist and STAT contributor Katherine Eban joins “The Readout LOUD” podcast to discuss the results of a two-year investigation.

Also on this week’s episode, we discuss Novartis’ effort to acquire MorphoSys, and the latest news on Eli Lilly and Novo Nordisk’s blockbuster obesity drugs with Elaine Chen, the newest member of STAT’s biotech reporting...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, Pharma, Pharma / Biotech, Trends
Related Articles:
STAT+: NVIDIA’s Kimberly Powell touts progress on AI in drug discovery
Big pharma ignores low-cost migraine solution
Sanders: Weight loss drug could bankrupt healthcare system
J&J Joins Chase for Hot Immunology Target With $850M Proteologix Acquisition
Going beyond A, B & O: Thermo Fisher unveils DNA test for the rarest blood types

Share This Article